NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR) AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	**Details of the person discharging managerial responsibilities/person closely associated**			
a)	Name	Saturn Invest AS		
2	**Reason for the notification**			
a)	Position/status	Saturn Invest AS is a close associate of Brynjar Forbergskog (primary insider and board member)		
b)	Initial notification /Amendment	Initial notification		
3	**Details of the issuer, an emission allowances market participant, auction platform, the auctioneer, or the auction monitor**			
a)	Business name	Lytix Biopharma ASA		
b)	LEI code	549300NXMIMRSBCDZO71		
4	**Details of the transaction(s): Section to be repeated for i) each type of instrument ii) each type of transaction, iii) each date, and iv) each place where the transaction(s) have been conducted**			
a)	Description of the financial instrument/type of instrument Identification code	Nature of instrument: Shares ISIN: NO0010405780		
b)	Nature of the transaction	Subscription and allocation of shares.		
c)	Price(s) and volume(s)	**Currency**	**Price(s)**	**Volume(s)**
		NOK	8.00	2,661,535
d)	Aggregated information - Aggregated volume - Aggregated price	 2,661,535 shares NOK 21,292,280		
e)	Date of the transaction	2026-11-17		
f)	Place of the transaction	XOFF – Outside a trading venue		

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR) AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	**Details of the person discharging managerial responsibilities/person closely associated**			
a)	Name	HIFO Invest AS		
2	**Reason for the notification**			
a)	Position/status	HIFO Invest AS is a close associate of Brynjar Forbergskog (primary insider and board member)		
b)	Initial notification /Amendment	Initial notification		
3	**Details of the issuer, an emission allowances market participant, auction platform, the auctioneer, or the auction monitor**			
a)	Business name	Lytix Biopharma ASA		
b)	LEI code	549300NXMIMRSBCDZO71		
4	**Details of the transaction(s): Section to be repeated for i) each type of instrument ii) each type of transaction, iii) each date, and iv) each place where the transaction(s) have been conducted**			
a)	Description of the financial instrument/type of instrument Identification code	Nature of instrument: Shares ISIN: NO0010405780		
b)	Nature of the transaction	Subscription and allocation of shares.		
c)	Price(s) and volume(s)	**Currency**	**Price(s)**	**Volume(s)**
		NOK	8.00	625,000
d)	Aggregated information - Aggregated volume - Aggregated price	 625,000 shares NOK 5,000,000		
e)	Date of the transaction	2026-11-17		
f)	Place of the transaction	XOFF – Outside a trading venue		

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR) AND PERSONS CLOSELY ASSOCIATED WITH THEM

<table>
<tr><td>1</td><td colspan="2">Details of the person discharging managerial responsibilities/person closely associated</td></tr>
<tr><td>a)</td><td>Name</td><td>Saturn Invest AS</td></tr>
<tr><td>2</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a)</td><td>Position/status</td><td>Saturn Invest AS is a close associate of Brynjar Forbergskog (primary insider and board member of Lytix Biopharma ASA)</td></tr>
<tr><td>b)</td><td>Initial notification/Amendment</td><td>Initial notification</td></tr>
<tr><td>3</td><td colspan="2">Details of issuer</td></tr>
<tr><td>a)</td><td>Name</td><td>Lytix Biopharma ASA</td></tr>
<tr><td>b)</td><td>LEI</td><td>549300NXMIMRSBCDZO71</td></tr>
<tr><td>4</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a)</td><td>Description of the financial instrument, type of instrument
Identification code</td><td>Nature of instrument: Shares

Instrument identification code (ISIN): NO0010405780</td></tr>
<tr><td>b)</td><td>Nature of the transaction</td><td>Lending of shares.</td></tr>
<tr><td>c)</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>0</td><td>1,118,247</td></tr></table>Transaction currency in NOK</td></tr>
<tr><td>d)</td><td>Aggregated information
- Aggregated volume
- Aggregated price</td><td>
1,118,247 shares
NOK 0</td></tr>
<tr><td>e)</td><td>Date of the transaction</td><td>2026-11-17</td></tr>
<tr><td>f)</td><td>Place of the transaction</td><td>XOFF – Outside of trading venue</td></tr>
</table>

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR) AND PERSONS CLOSELY ASSOCIATED WITH THEM

<table>
<tr><td>1</td><td colspan="2">Details of the person discharging managerial responsibilities/person closely associated</td></tr>
<tr><td>a)</td><td>Name</td><td>Gjest Breistein</td></tr>
<tr><td>2</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a)</td><td>Position/status</td><td>Primary insider (CFO of Lytix Biopharma ASA)</td></tr>
<tr><td>b)</td><td>Initial notification/Amendment</td><td>Initial notification</td></tr>
<tr><td>3</td><td colspan="2">Details of issuer</td></tr>
<tr><td>a)</td><td>Name</td><td>Lytix Biopharma ASA</td></tr>
<tr><td>b)</td><td>LEI</td><td>549300NXMIMRSBCDZO71</td></tr>
<tr><td>4</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a)</td><td>Description of the financial instrument, type of instrument
Identification code</td><td>Nature of instrument: Shares

Instrument identification code (ISIN): NO0010405780</td></tr>
<tr><td>b)</td><td>Nature of the transaction</td><td>Allocation and acquisition of shares.</td></tr>
<tr><td>c)</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>8.00</td><td>12,500</td></tr></table>Transaction currency in NOK</td></tr>
<tr><td>d)</td><td>Aggregated information
Aggregated information
- Aggregated volume
- Aggregated price</td><td>

12,500 shares
NOK 100,000</td></tr>
<tr><td>e)</td><td>Date of the transaction</td><td>2026-11-17</td></tr>
<tr><td>f)</td><td>Place of the transaction</td><td>XOFF – Outside of trading venue</td></tr>
</table>

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR) AND PERSONS CLOSELY ASSOCIATED WITH THEM

<table>
<tr><td>1</td><td colspan="2">Details of the person discharging managerial responsibilities/person closely associated</td></tr>
<tr><td>a)</td><td>Name</td><td>Øystein Rekdal</td></tr>
<tr><td>2</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a)</td><td>Position/status</td><td>Primary insider (CEO of Lytix Biopharma ASA)</td></tr>
<tr><td>b)</td><td>Initial notification/Amendment</td><td>Initial notification</td></tr>
<tr><td>3</td><td colspan="2">Details of issuer</td></tr>
<tr><td>a)</td><td>Name</td><td>Lytix Biopharma ASA</td></tr>
<tr><td>b)</td><td>LEI</td><td>549300NXMIMRSBCDZO71</td></tr>
<tr><td>4</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a)</td><td>Description of the financial instrument, type of instrument
Identification code</td><td>Nature of instrument: Shares

Instrument identification code (ISIN): NO0010405780</td></tr>
<tr><td>b)</td><td>Nature of the transaction</td><td>Allocation and acquisition of shares.</td></tr>
<tr><td>c)</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>8.00</td><td>12,500</td></tr></table>Transaction currency in NOK</td></tr>
<tr><td>d)</td><td>Aggregated information
- Aggregated volume
- Aggregated price</td><td>
12,500 shares
NOK 100,000</td></tr>
<tr><td>e)</td><td>Date of the transaction</td><td>2026-11-17</td></tr>
<tr><td>f)</td><td>Place of the transaction</td><td>XOFF – Outside of trading venue</td></tr>
</table>

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR) AND PERSONS CLOSELY ASSOCIATED WITH THEM

<table>
<tr><td>1</td><td colspan="2">Details of the person discharging managerial responsibilities/person closely associated</td></tr>
<tr><td>a)</td><td>Name</td><td>Baldur Sveinbjørnsson</td></tr>
<tr><td>2</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a)</td><td>Position/status</td><td>Primary insider (CSO of Lytix Biopharma ASA)</td></tr>
<tr><td>b)</td><td>Initial notification/Amendment</td><td>Initial notification</td></tr>
<tr><td>3</td><td colspan="2">Details of issuer</td></tr>
<tr><td>a)</td><td>Name</td><td>Lytix Biopharma ASA</td></tr>
<tr><td>b)</td><td>LEI</td><td>549300NXMIMRSBCDZO71</td></tr>
<tr><td>4</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a)</td><td>Description of the financial instrument, type of instrument
Identification code</td><td>Nature of instrument: Shares

Instrument identification code (ISIN): NO0010405780</td></tr>
<tr><td>b)</td><td>Nature of the transaction</td><td>Allocation and acquisition of shares.</td></tr>
<tr><td>c)</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>8.00</td><td>6,250</td></tr></table>Transaction currency in NOK</td></tr>
<tr><td>d)</td><td>Aggregated information
Aggregated information
- Aggregated volume
- Aggregated price</td><td>

6,250 shares
NOK 50,000</td></tr>
<tr><td>e)</td><td>Date of the transaction</td><td>2026-11-17</td></tr>
<tr><td>f)</td><td>Place of the transaction</td><td>XOFF – Outside of trading venue</td></tr>
</table>